Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first...

Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

Safety and efficacy of atezolizumab plus bevacizumab for unresectable...

Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA

Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma ( Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA )

Cemiplimab plus ipilimumab for advanced NSCLC

Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea

Cemiplimab plus ipilimumab for advanced NSCLC ( Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea )

Real world data and diagnostics in patients with NSCLC with EGFR exon 20...

Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio...

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Promise of personalised medicine for patients with prostate cancer

Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt...

Promise of personalised medicine for patients with prostate cancer ( Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt Attard )

Oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell...

Dr Todd Michael Bauer - Sarah Cannon Research Institute and Tennessee Oncology...

Oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma ( Dr Todd Michael Bauer - Sarah Cannon Research Institute and Tennessee Oncology, Nashville, USA )

Latest developments in the treatment of mRCC

Prof Javier Puente, Prof Jens Bedke, Prof James Larkin and Prof Viktor Grünwald

Latest developments in the treatment of mRCC ( Prof Javier Puente, Prof Jens Bedke, Prof James Larkin and Prof Viktor Grünwald )

mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early...

Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt...

mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early treatment? ( Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt Attard )

Evolving medical treatment in advanced/recurrent endometrial cancer

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

Evolving medical treatment in advanced/recurrent endometrial cancer ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

Diagnosis, testing and biomarkers in the individualisation of patient care with...

Prof Andrea Necchi and Prof Eva Compérat

Diagnosis, testing and biomarkers in the individualisation of patient care with FGFR mutated bladder cancer ( Prof Andrea Necchi and Prof Eva Compérat )

More from ecancer